Current Report Filing (8-k)
April 13 2021 - 5:27PM
Edgar (US Regulatory)
0001034842
false
0001034842
2021-04-13
2021-04-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 13, 2021
RIGEL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
0-29889
|
|
94-3248524
|
|
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
|
|
|
1180 Veterans Boulevard
|
|
|
South San Francisco, CA
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (650) 624-1100
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Title of Each Class
|
|
Trading
Symbol(s)
|
|
Name of Each Exchange on
Which Registered
|
Common Stock, par value $0.001 per share
|
|
RIGL
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other
Events
On
April 13, 2021, Rigel Pharmaceuticals, Inc. (“Rigel”) announced positive topline results from a multi-center, Phase 2
clinical trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase inhibitor, for the treatment of hospitalized patients
with COVID-19. A copy of Rigel’s press release, titled “Positive Topline Data Shows Fostamatinib Meets Primary Endpoint
of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19,” is attached as Exhibit 99.1 to this Current Report
and is incorporated by reference herein.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 13, 2021
|
RIGEL PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ Dolly A. Vance
|
|
|
Dolly A. Vance
|
|
|
Executive Vice President, General Counsel and Corporate
Secretary
|
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From Apr 2023 to Apr 2024